For decades, Herbert Kleber, M.D., had been one of the country's most important researchers in substance use disorder treatment. He died last month of a heart attack while on vacation in Greece with his family. He was a pioneer in addiction treatment, focusing on the need for evidence in the 1970s, when the entire field was barely taken seriously. His insistence on randomized controlled trials and placebo comparisons helped give the field credibility. He even spent two years working at the newly minted Office of National Drug Control Policy, but it wasn't a good fit for him, as he was a treatment, not a “war on drugs,” proponent. At Columbia University, he established the division on substance use disorder with addiction researcher Marian Fischman, Ph.D., his second wife, who died in 2001. When he died, Kleber was still professor of psychiatry there, and emeritus director of the division. We interviewed him many times over the years; he was always generous with his comments and analysis. He was co‐author of the seminal “Drug Dependence, a Chronic Medical Illness: Implications for Treatment, Insurance, and Outcomes Evaluation,” which he wrote with A. Thomas McLellan, Ph.D.; David C. Lewis, M.D.; and Charles P. O'Brien, M.D., and was published in the Oct. 4, 2000, issue of the Journal of the American Medical Association.
Read full abstract